Endogenous gut microbiome and implanted intranasal E. coli-Nissle modulate cancer tissues metabolism in 4T1 syngeneic tumor bearing mice - 07/01/26
, Ivaylo Gentschev b, 1, Cornelia Prehn a, Stefanie Hauck a, Michael Witting a, Ivan Petrov b, Mingyu Ye b, Eman M. Othman b, ⁎
, Aladar A. Szalay b, c, d, ⁎ 
Abstract |
Despite recent progress in the diagnosis and treatment of advanced cancers, the overall patient treatment outcome did not substantially improve over the last years. Therefore, developing novel therapies, which may also work synergistically in combination with the conventional therapies is crucial. One promising new therapeutic approach is bacterium-mediated cancer therapy. In the current work, we describe the influence of the gut microbiome and intranasal E. coli Nissle applications on the metabolism in cancer tissues of 4T1 syngeneic tumor bearing mice. Here we found that after gut microbiome depletion and/or E. coli Nissle treatment the ratios of ADMA/Arginine, Putrescine/Ornithine and Kynurenine/Tryptophan as well as the total concentration of Carnosine, Kynurenine and H1 (synonymus for all sugars detectable) are significantly altered in tumor tissues of as the result of treatment. In conclusion, our current data show that E. coli Nissle bacteria facilitating metabolic modulation of tumors, a finding could be important for improved cancer therapy in patients.
Le texte complet de cet article est disponible en PDF.Keywords : Anticancer, Gut microbiome, E. coli Nissle, 4T1 syngeneic tumor
Plan
Vol 193
Article 118750- décembre 2025 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
